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ABSTRACT 
 
Background  
Acute kidney injury (AKI) is a condition with high rates of mortality and morbidity in the 
hospital setting. Various factors, such as social, political and ethical dilemmas are closely 
associated with scarce resources in the management of AKI in Africa. We therefore 
reviewed the demography, causes and outcomes of AKI at Chris Hani Baragwanath 
Academic Hospital (CHBAH). 
Methods  
A retrospective review of 324 patients with renal failure who were initiated on acute dialysis 
at the CHBAH over the periods of 1 July 2009 to 30 June 2011 was done.  
Results  
The mean age at presentation with AKI was 40±13 years. Males accounted for 57% whist 
92% of the total cohort were Black. HIV positivity occurred in 26% of patients, whilst 4% and 
2% of the cohort had Hepatitis B and C infection respectively. The leading causes for 
initiation of acute dialysis included decompensated chronic kidney disease (38.9%), acute 
tubular necrosis (ATN) (38.3%), HIV related kidney disease (13.6%), pregnancy-related 
kidney disease (7.4%), glomerulonephritis (7.4%) and malaria (5.7%). Acute tubular 
necrosis due to sepsis was the predominant cause of AKI in HIV positive patients. 
Decompensated chronic kidney disease was present in a large proportion of patients, 
suggesting that chronic co-morbid diseases such as hypertension and diabetes mellitus 
occurred in a large proportion of the general population. Medical referrals accounted for 78% 
of the patients presenting with AKI.  
 
 v 
Renal recovery occurred in patients presenting with a lower average pre-dialysis blood urea 
level of 34±19 mmol/l, compared to higher levels seen in patients with poorer outcomes (p 
<0.0001). Pregnancy- related kidney injury had the lowest average pre-dialysis blood urea 
levels of 20±6 mmol/l. The average pre-dialysis serum creatinine in patients with renal 
recovery was 804±467 μmol/l compared to those with poorer outcomes, that had average 
serum creatinine levels of greater than 1000 μmol/l at initiation of dialysis (p <0.0001).  
 
The overall renal recovery rate was 31%, with a mortality rate of 23%. Failure to regain renal 
function with subsequent chronic consequences occurred in 44.6% of patients, of which 
23% were transferred to chronic renal replacement therapy and the remaining 21.6% of 
patients were transferred to Renal out patients department with cessation of acute dialysis. 
 
HIV positive patients had a greater renal recovery rate (36% vs 26%); however they had a 
higher mortality rate compared to their HIV negative counterparts (34% vs 19%); (p 
<0.0001). HIV positive patients with CD4 counts greater than 200 cells/μl had a 46% renal 
recovery rate compared to 30% in patients with CD4 counts less than 200 cells/μl 
(p=0.1894). Mortality with CD4 counts less than 200 cells/μl was 38% compared to 26% in 
patients with CD4 counts greater than 200 cells/μl (p=0.1894).  Mortality rates were similar 
in HIV positive patients treated with antiretrovirals (ARVs) compared to those that were 
ARV-naive (p =0.5857). 
 
Pregnancy-related kidney injury and malaria both had high rates of renal recovery, 92% and 
79% respectively. 
  
 
 vi 
Discussion 
 
The mean age of presentation of AKI were consistent with other studies in developing 
countries but was substantially lower than in developed countries such as the United 
Kingdom and Spain. The underlying aetiology of AKI at CHBAH resembles that of other 
developing nations with ATN, malaria and pregnancy-induced kidney injury being amongst 
the leading causes. Acute tubular necrosis still remains a common cause of AKI in South 
Africa as previously documented by Seedat et al. Malignancy and obstructive uropathy 
occurs at a much lower frequency compared to developed nations. The leading cause in HIV 
positive patients is ATN secondary to sepsis. Mortality occurred in 23% of the cohort, with 
HIV positive patients having a much higher mortality of 34%, concurring with a 
Johannesburg-based study by Vachiat et al.  
 
Initiating dialysis at lower blood urea and serum creatinine levels in all patent groups had a 
much better outcome, including in HIV positive patients.  
 
Conclusion  
AKI remains a common presentation that frequently requires dialysis, a scarce resource in 
an already overburdened health system, with a high mortality rate. HIV positive patients had 
a higher mortality rate compared to HIV negative patients; however a higher renal recovery 
rate was observed in this group. CD4 count and ARV status had no statistical significant 
effect on outcomes, probably due to the small sample size. 
 
 
 
 vii 
ACKNOWLEDGEMENTS 
 
 
 
Professor S Naicker, a brilliant person, leader, mentor, academic and my co supervisor, 
whose encouragement and commitment to this project was unparalleled. Every step in this 
journey was carefully guided by Professor Naicker. For this, I will always be grateful to have 
been given the opportunity of working with someone of this magnitude in the Nephrology 
world. 
 
Dr M. Mashabane, Head of the Renal Unit at CHBAH, my co supervisor. I am eternally 
grateful for the help and support that you have provided for me during these last few years. 
 
Dr A Bentley, who assisted me with ideas, reviews and statistics. 
 
Dr Firdous Variava, my dear and amazing wife, who assisted me with data collection and 
statistics. 
 
Mr Living Shivambo, a patient at CHBAH who assisted me with data collection, unfortunately 
demised prior to the completion of this project. 
 
Lastly and most importantly, the patients at CHBAH, without whom this project would not be 
possible. 
 
 
 
 
 
 
 viii 
TABLE OF CONTENTS 
 
DECLARATION ............................................................................................................................................. ii 
DEDICATION ................................................................................................................................................ iii 
ABSTRACT................................................................................................................................................... iiv 
Background ............................................................................................................................................................. iiv 
Methods .................................................................................................................................................................... iiv 
Results ...................................................................................................................................................................... iiv 
Discussion ................................................................................................................................................................. vi 
Conclusion ................................................................................................................................................................ vi 
ACKNOWLEDGEMENTS ........................................................................................................................ vii 
TABLE OF CONTENTS ............................................................................................................................... viii 
LIST OF TABLES .............................................................................................................................................. x 
LIST OF FIGURES ........................................................................................................................................... xi 
ABBREVIATIONS ......................................................................................................................................... xii 
CHAPTER 1. LITERATURE REVIEW .................................................................................................... 1 
1.1 Historical Perspective .................................................................................................................................... 1 
1.2 Definitions of acute kidney injury............................................................................................................... 2 
1.3 Biomarkers and acute kidney injury ........................................................................................................ 6 
1.4 Epidemiology of acute kidney injury ....................................................................................................... 8 
1.5 Causes of acute kidney injury ................................................................................................................. 10 
1.5.1 Acute tubular necrosis and acute kidney injury .......................................................................................13 
1.5.2 Tubulo-interstitial nephritis and acute kidney injury ..............................................................................15 
1.5.3. HIV and acute kidney injury .............................................................................................................................16 
1.5.4 Malaria and acute kidney injury .......................................................................................................................20 
1.5.5 Pregnancy and acute kidney injury ................................................................................................................22 
1.5.6 Malignancy and acute kidney injury ..............................................................................................................23 
1.5.7 Other causes of acute kidney injury ..............................................................................................................24 
1.6. Treatment of acute kidney injury .......................................................................................................... 25 
1.6.1 Supportive treatment .............................................................................................................................................25 
1.6.2 Dialysis ................................................................................................................................................................ .........26 
1.7 Timing of dialysis .......................................................................................................................................... 28 
1.8 Outcomes of acute kidney injury ........................................................................................................... 28 
1.9 Justification for study ................................................................................................................................. 30 
1.10 Aims and Objectives.................................................................................................................................. 31 
1.10.1 Aims ............................................................................................................................................................................31 
1.10.2 Objectives ................................................................................................................................................................31 
CHAPTER 2: METHODS ......................................................................................................................... 32 
2.1 Study Design ................................................................................................................................................... 32 
2.1.1 Inclusion criteria ......................................................................................................................................................32 
2.1.2 Exclusion criteria .....................................................................................................................................................32 
2.2 Ethics .................................................................................................................................................................. 33 
2.3 Data collection and analysis .................................................................................................................... 33 
2.4 Definitions of outcomes measured ....................................................................................................... 35 
CHAPTER 3: RESULTS ........................................................................................................................... 37 
3.1 All Patients ....................................................................................................................................................... 37 
 ix 
3.1.1 Demography and clinical data ..........................................................................................................................37 
3.1.2 HIV, Hepatitis B and Hepatitis C status .......................................................................................................38 
3.1.3 Decompensated Chronic Kidney Disease .................................................................................................40 
3.1.4 Discipline of referral ...............................................................................................................................................41 
3.1.5 Causes of kidney injury .......................................................................................................................................41 
3.2 HIV infection and acute kidney injury................................................................................................... 44 
3.2.1 Demography and clinical data of HIV positive patients .......................................................................44 
3.2.2 Causes of kidney injury in HIV positive patients .....................................................................................46 
3.3 Demography and clinical data of patients with malaria ............................................................... 47 
3.4 Demography and clinical data in pregnancy-related kidney injury ......................................... 48 
3.5 Outcomes .......................................................................................................................................................... 49 
3.5.1 Pre dialysis blood urea and outcomes .........................................................................................................49 
3.5.2 Pre-dialysis serum creatinine levels and outcomes ..............................................................................50 
3.5.3 Causes of acute kidney injury and outcomes ...........................................................................................51 
3.5.4 HIV infection and outcomes ..............................................................................................................................53 
CHAPTER 4: DISCUSSION ......................................................................................................................... 56 
4.1 Demography of patients presenting for acute dialysis ..................................................................... 56 
4.2 Decompensated chronic kidney disease and co-morbidities ......................................................... 58 
4.3 Causes of acute kidney injury..................................................................................................................... 58 
4.4 HIV and kidney injury – Demography and clinical data ................................................................... 62 
4.5 The pre-dialysis blood urea and serum creatinine and outcomes .......................................... 63 
4.6 Outcomes in all patients with kidney injury ...................................................................................... 65 
4.7 Outcomes based on HIV status ............................................................................................................... 66 
4.8 Limitations ........................................................................................................................................................ 67 
4.9 Recommendations ........................................................................................................................................ 69 
4.10 Conclusion ..................................................................................................................................................... 69 
CHAPTER 5: REFERENCES ................................................................................................................. 71 
CHAPTER 6: APPENDIX ......................................................................................................................... 89 
APPENDIX A: Ethics clearance certificate ................................................................................................. 89 
Appendix B: Data Collection Sheet .............................................................................................................. 90 
    Appendix C: Turnitin letter from supervisor……………………………………………………….90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
LIST OF TABLES  
Table1: Stages of AKI ............................................................................................................................................. 5 
Table 2: Biomarkers in AKI ................................................................................................................................. 6 
Table 3. Causes of AKI in Africa ................................................................................................................... 12 
Table 4: Classification of AKI in HIV........................................................................................................... 16 
Table 5: Demography of patients that underwent acute dialysis ............................................. 37 
Table 6: Causes of ATN ...................................................................................................................................... 42 
Table 7: Type of malignancies ....................................................................................................................... 43 
Table 8: Demography and clinical data for HIV positive patients ............................................ 44 
Table 9: Median CD4 counts related to ARV status .......................................................................... 45 
Table 10: Causes of kidney injury in HIV positive and HIV negative patients .................. 46 
Table 11: Top 5 causes of kidney injury in HIV positive patients............................................. 46 
Table 12: Demography and clinical data of patients with malaria ........................................... 47 
Table 13: Demography and clinical data of patients with pregnancy-related kidney 
injury .................................................................................................................................................................... 48 
Table 14: Causes of pregnancy-related kidney injury ..................................................................... 48 
Table 15: Pre-dialysis blood urea (mmol/l) in all patients ............................................................. 49 
Table 16: Pre-dialysis serum creatinine levels (μmol/l) for all patients ................................ 50 
Table 17: Outcomes in all patients  ............................................................................................................. 51 
Table 18: Outcomes of the leading causes of kidney injury ....................................................... 51 
Table 19: Outcomes in HIV positive vs HIV negative patients ................................................... 53     
 xi 
LIST OF FIGURES   
Figure 1: RIFLE and AKIN Classification .................................................................................................... 4 
Figure 2: Comparison of biomarkers concentrations related to time ....................................... 7 
Figure 3: Causes of acute kidney injury .................................................................................................. 11 
Figure 4: Reported cases of Malaria in 2011 ......................................................................................... 20 
Figure 5:Race of patients on acute dialysis  ......................................................................................... 38 
Figure 6: Gender of patients on acute dialysis .................................................................................... 38 
Figure 7: HIV status of patients on acute dialysis ............................................................................. 38 
Figure 8: Hepatitis B serology of patients on acute dialysis ...................................................... 39 
Figure 9: Hepatitis C serology of patients on acute dialysis ...................................................... 39 
Figure 10: Decompensated chronic kidney disease ........................................................................ 40 
Figure 11: Causes of kidney injury ............................................................................................................. 41 
Figure 12: Outcomes in HIV positive patients ..................................................................................... 53 
Figure 13: Outcomes in HIV positive patients based on CD4 count....................................... 54 
Figure 14: Outcomes in HIV positive patients based on ARV status ..................................... 55 
  
 
       
 xii 
  
ABBREVIATIONS  
 
ACE Angiotensin converting enzyme 
ADQI Acute Dialysis Quality Initiative 
AKI Acute kidney injury 
AKIN Acute Kidney Injury Network 
ARF Acute renal failure 
ARV Antiretroviral 
ATN Acute tubular necrosis 
CHBAH Chris Hani Baragwanath Academic Hospital 
ESRD End stage renal disease 
FSGS Focal segmental glomeruosclerosis 
GN Glomerulonephritis 
HAART Highly active antiretrovirals 
HD Haemodialysis 
HELLP Acronym for Haemolysis, Elevated Liver enzymes, Low Platelets 
HIV Human immunodeficiency virus 
HIVAN Human immunodeficiency virus associated nephropathy 
HIVICK Human immunodeficiency virus immune complex kidney disease 
HUS Haemolytic uraemic syndrome 
ICU Intensive care unit 
NRTI Nucleoside reverse transcriptase inhibitors 
NSAIDS Non steroidal anti inflammatory drugs 
PD Peritoneal dialysis 
RIFLE Acronym for Risk, Injury, Failure, Loss and End stage disease 
ROPD Renal outpatient department 
RRT Renal replacement therapy 
SIRS Systemic inflammatory response syndrome 
SLE Systemic lupus erthyematosis 
TDF Tenofovir 
TIN Tubulo interstitial nephritis 
TTP Thrombotic thrombocytopaenic purpura     
 xiii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
CHAPTER 1. LITERATURE REVIEW 
 
 
1.1 Historical Perspective 
 
The evidence of kidney disease historically dates back to the time of the ancient Egyptians 
(1). Egyptians were one of the first civilizations to begin collecting and recording medical 
knowledge due to their constant desire for eternal life. The preservation of their knowledge 
in medical papyri reflects the great capacity of Egyptians for treating symptoms, but lacks 
the abstract thought that was to come with the more rational Greek medical era. Multiple 
references are made to symptoms such as haematuria, urinary retention, frequency and 
infection in ancient Egyptian records (1). These accounts have been matched by the 
Greeks, Romans and Byzantines who also correlated clinical syndromes with certain 
diseases that affect the kidney (2). These include pyuria, pain and fever indicative of 
diseases such as pyelonephritis, kidney abscess formation as well as the relationship 
between systemic sepsis and oliguria. These ancient records can all be extrapolated in 
modern times as the major aspects of acute kidney injury (AKI). 
 
Hippocrates, one of the most influential people of all times, has made huge contributions to 
medical knowledge (3). Hippocratic medicine laid the foundation of the development of 
clinical nephrology and he is considered the “Father of Nephrology” (4). Despite the huge 
advances in modern renal medicine, Hippocratic practices, emphasizing clinical 
observations, prognostication and ethical influences can never be overlooked and are part 
and parcel of not only medicine but plays a large role within the nephrology world (5).  
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During the renaissance period many medical advances were made; however, the 
association of oedema with renal failure was only identified in the late 18th century (6). 
Proteinuria was discovered in this period facilitating the birth of the modern approach to 
kidney disease (7). Bright provided the first complete clinical description of the various forms 
of acute and chronic glomerulonephritis (GN) with accompanying macroscopic changes in 
1827 (8, 9). His contribution to the nephrology world has proven to be enormous. The 
amount of new knowledge acquired during the 20th century has been tremendous, and 
covers all the mechanisms of urine formation, the role of sodium retention in oedematous 
states, the physiology and pathophysiology of the renin-angiotensin-aldosterone system, 
nephrotic and nephritic syndromes, new methods of investigation, progress in histology and 
immunology, the discovery of many tubular syndromes, the introduction of antibiotics and 
antihypertensive drugs and the development of dialysis. These advancements in nephrology 
have led us to the modern age of renal medicine that encompasses a vast array of 
pathology and disease processes. 
 
1.2 Definitions of acute kidney injury  
 
Acute kidney injury is characterized by a decline in kidney function that can manifest over a 
few hours to days. This leads to an increase in nitrogenous waste products within the 
bloodstream, resulting in the symptoms that may become apparent during the illness (10). 
 
The lack of a standard definition of AKI has impacted on the progress of clinical and basic 
research in this field (11). A review of 26 studies involving post operative renal failure in the 
mid nineties showed that no two studies used the same definition when defining acute renal 
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failure (ARF) (12).  This highlights the inconsistencies within the medical fraternity and AKI. 
Until recently, no consensus existed on how best to define, characterize, and study AKI. 
 
The Acute Dialysis Quality Initiative (ADQI) group of experts developed and published the 
RIFLE criteria in 2004 (13, 14). The RIFLE classification has become the most widely used 
and adopted method of standardization of AKI with almost 30 studies using this definition. 
These criteria, which make up the acronym 'RIFLE', classify renal dysfunction according to 
the degree of impairment present: risk (R), injury (I), failure (F), sustained loss (L) and end-
stage kidney disease (E) (15). This new classification system has transformed acute kidney 
disease. This disease entity can now be viewed as a spectrum of kidney disease and hence 
the emergence of the term, AKI rather than ARF (16). 
 
The RIFLE scoring system has been reviewed and studied in many centres around the 
world, particularly in critically ill patients. The results have been consistent in various 
studies. In a large heterogeneous cohort of critically ill patients, the increase in severity of 
RIFLE categories is associated with an increase in mortality (17). The RIFLE classification  
(Figure 1) is a simple, readily available clinical tool to classify AKI in different population 
groups (18).  
 
In 2007, The Acute Kidney Injury Network (AKIN) made a few modifications to the RIFLE 
criteria resulting in the birth of the AKIN criteria (Figure 1). The first 3 stages are kept with a 
few minor changes. These are called AKIN Stage 1, AKIN Stage 2 and AKIN Stage 3. The 
loss and end stage kidney disease categories of the RIFLE classification do not feature in 
the AKIN classification. 
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The two classifications, seen in Figure 1, can detect AKI with both high sensitivity specificity 
and describe severity levels that predict the prognosis of affected individuals, particularly 
those in intensive care (15). Both the RIFLE and AKIN classification utilize an increase in 
serum creatinine level from baseline as well as a decrease in urine output (19). These 
surrogate markers of renal impairment usually manifest much later after kidney injury, 
however are readily available in clinical practice (20). 
 
 
 
 
 
Figure 1: RIFLE and AKIN Classification  
 
 
Reference: www.ccforum.com (Accessed from the internet in February 2013) (21) 
 
 
Direct comparison of the 2 classifications show similar sensitivity and ability to predict 
outcomes in ill patients (20). 
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The KDIGO guideline (22), published in 2012, defines AKI based on  any of the following: 
- Increase in serum creatinine of greater than 26.5μmol/l within 48 hours; or 
- Increase in serum creatinine of greater than 1.5 times the baseline over 48 hours; 
or 
- Urine output of less than 0.5ml/kg/hr for 6 hours. 
The stages of AKI based on the KDIGO guidelines are presented in Table 1. These stages 
have prognostic value and resemble the AKIN classification.  
 
 
Table1: Stages of AKI   
Stage Cr. Criteria Urine Output Criteria 
1 
 
 
SCr X 1.5-1.9 times baseline 
                or 
a rise of ≥ 26.5μmol/l 
UO < 0.5ml/kg/hr x 
6hrs 
 
2 
 
SCr X 2-2.9 times baseline 
 
UO < 0.5ml/kg/hr x 
12 hrs 
3 
 
 
 
 
 
 
SCr X 3 times baseline 
                or 
 a rise ≥ 353.6 μmol/l 
                or 
Initiation of renal replacement therapy  
                or  
a decrease in eGFR of < 35ml/min/1.73m 
UO < 0.3ml/kg/hr x 
24 hrs or Anuria ≥hrs 
 
 
 
 
 
 Reference:  Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clinical practice. 
2012;120(4):179-84. (22) 
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1.3 Biomarkers and acute kidney injury 
 
Acute kidney injury is a serious abnormality that results in severe metabolic, electrolyte and 
fluid abnormalities in the body. These effects occur later in the presentation of AKI and 
serum biomarkers such as serum creatinine increase later in the disease (23), thus 
emergence of biomarkers for the earlier detection of AKI are currently being explored. At 
present, serum creatinine is the only readily available biomarker in clinical practice and is 
the gold standard. 
 
Biomarkers can be divided into 4 main categories that include functional markers, up-
regulated proteins, low molecular weight proteins and enzymes (24).  
 
Table 2: Biomarkers in AKI 
Functional markers 
 
Up regulated proteins 
 
Low molecular 
weight proteins 
Tubular enzymes 
 
Serum creatinine 
 
Nuetrophil gelatinase-
associated lipocalin (NGAL) 
Urine cystatin C 
 
Alpha-glutathione s-
transferase (α-GST) 
Plasma/serum 
cystatin C 
 
Kidney injury molecule-1 (KIM-
1) 
   
Pi-glutathione s-
transferase (π-GST) 
 
  
Liver fatty acid binding 
protein(L-FABP)   
Gammaglutanyl 
transpeptidase (GGT) 
  
Interleukin-18 (IL-18) 
   
Alkaline phosphatase 
(ALP) 
      
N-acetyl-β-D-
glucosaminidase(NAG) 
de Gues H.R.H et al – Biomarkers for the prediction of acute kidney injury: a narrative review on the current 
status and future challenges. Clin Kidney J (2012) 5:102-108 (24) 
 
The biomarkers represented in Table 2 are directly related to the pathophysiology of kidney 
injury at various cellular levels. The majority of these markers are expensive but importantly 
are only beginning to be explored as a research tool within the nephrology world. These 
markers rise very early in the course of AKI and have the potential for earlier detection of 
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AKI as seen in Figure 2. The biomarkers depicted in Figure 2 clearly show the peaked 
levels of concentration of the biomarkers occur much earlier after an insult compared to 
serum creatinine levels. 
 
Figure 2: Comparison of biomarkers concentrations related to time 
 
Reference: Zheng CM et al. Biomarkers in acute kidney injury. OJ Neph. 2013;3(1):51-60. (25) 
 
Biomarkers have been studied in various centres around the world with varying results 
obtained (24). The majority of the studies evaluated the various biomarkers independently 
of each other. Results currently indicate that biomarkers have a potential role to play in the 
earlier diagnosis of AKI but larger studies need to be performed in order to utilize these 
markers in clinical practice. They are also reported to have prognostic implications. Clinical 
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appraisal of a patient using serum creatinine remains the cornerstone  of diagnosis at 
present (26). 
 
1.4 Epidemiology of acute kidney injury  
The incidence of AKI around the world is not well known (27). Studies done in the United 
States of America have shown incidences of 23.8 per 1000 with an 11% yearly increase 
from 1992 to 2001(28). Similar results were obtained from a Spanish review published in 
1996, showing an increase in the rate of AKI in recent times, with a significant contribution 
from iatrogenic causes as well as the development of AKI in the peri-operative period (29). 
 
Acute kidney injury has been reported to occur in 1% of hospital admissions (30). 
Approximately 2-5% (31) are affected by kidney injury during hospitalisation and as many 
as 15% of patients develop AKI after certain types of surgery such as cardiopulmonary 
bypass surgery (23). 
 
The pattern of AKI in emerging countries is changing, albeit at a slower pace compared to 
that in developed countries. A study done in Northern India showed a vast difference in the 
rates of AKI between two different time frames. There was a decline from 23% to 10% in 
patients with AKI caused by diarrhoeal illness from the periods 1965-1974 and 1981-1986 
respectively. A similar decline was also noted with sepsis-related AKI, however the overall 
causes and actual frequencies are different from the developed countries with regards to 
community-acquired AKI (32). A second study compiled by the same group in India 
assessed spectrums of hospital-acquired AKI in developing countries and found that results 
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were similar to that of technologically advanced countries, although the pattern of 
community acquired AKI is vastly different (33). 
 
Martin Luther King once commentated "Of all the forms of inequality, injustice in health is 
the most shocking and the most inhumane." There has been a clear discrepancy between 
the epidemiology between developed and developing world (34). Socio-economic 
discrepancies are one of the major contributors to the disparities between these two worlds. 
Together with cultural practices, infective pathology as well as availability of resources, 
these have resulted in the current epidemiological pattern of AKI that is seen in the 
developing world.  
 
The differences between developed and developing countires are caused by various 
factors. Financial implications are probably one of the most important aspects. Money has 
always driven the world and the medicine is no exception. More money translates to more 
research, better drug development, easy access to these medications and health care, all of 
which enables the developed countries to move forward. With financial backing, richer 
nations have an overall better healthcare infrastructure and resources and improved access 
to healthcare. Resources such as dialysis and better equipment are pivotal in improving 
mortality from renal disease. These challenges have been one of the largest factors in the 
high levels of morbidity and mortality in Africa.  
 
The social aspect of a nation is often neglected when assessing disease. The socio-political 
scene of any nation is essentially the driving force of the country and dictates the above 
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factors directly. Poor sanitation, housing, overcrowding and poverty are just a few examples 
that have been shown to have major effects on disease epidemics in developing nations. 
Many outbreaks such as diarrhoeal illness secondary to poor sanitation, have been seen in 
developing nations almost exclusively, with high mortality rates (35).  
 
Acute kidney injury in the developed world is often seen in the geriatric population. 
Functional changes that occur in the ageing kidney lead to a reduced glomerular filtration 
rate, lower renal blood flow and impaired renal auto-regulation (36). AKI is often iatrogenic 
and multifactorial, commonly superimposed on pre-existing renal dysfunction, and resulting 
from exposure to nephrotoxins such as radio contrast agents, aminoglycosides, NSAIDs, 
ACE inhibitors and diuretics. 
 
1.5 Causes of acute kidney injury 
Acute kidney injury comprises of a diverse spectrum of disease entities. It can be assessed 
as a syndrome or constellation of features whereby a decline in kidney function occurs, 
ultimately resulting in severe morbidity and mortality, if not recognized and treated 
adequately. 
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Figure 3: Causes of acute kidney injury  
 
www.pharmaworld.pk.cws3.com (Accessed from the internet in May 2013) (37) 
 
Various mechanisms are involved in the pathophysiology of AKI. These insults render the 
functional unit of the kidney, the nephron, with reduced capabilities of fulfilling its functions. 
These functions include urine production, fluid balance, maintenance of electrolyte balance, 
excretion of toxic substances and ability to accomplish the important endocrine functions of 
the kidney. All of these functions are interrupted substantially, leading to the signs and 
symptoms that develop in AKI (10). 
 
 
The causes of AKI in Africa have a different pattern when compared to Europe, Australia or 
the United States of America. Infective causes, both HIV-related sepsis and non-HIV related 
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diseases are amongst the major contributors to AKI. Naicker et al, reviewed the major 
causes of AKI in Africa as seen in Table 3. Infective causes such as malaria, diarrhoeal 
illness, HIV, obstetrical causes and toxins were the leading causes of AKI in Africa and 
similar patterns were seen in various regions of Africa (34). 
 
Table 3. Causes of AKI in Africa  
Country Causes of AKI 
North Africa  
Algeria Toxins, trauma/surgery, urologic 
Egypt Surgical, toxins, obstructive 
Morocco Haemodynamics, sepsis, obstructive 
  
West Africa  
Cameroon Malaria, obstetric, toxins 
Cote d'Ivore Malaria, HV, toxin 
Nigeria Sepsis, obstetric, toxin 
Senegal Obstetric, malaria, herbal toxins 
Democratic Republic of 
Congo 
Infections (especially malaria), hypovolaemia, 
toxin 
  
East Africa  
Kenya Infection, obstetric, surgical 
Burundi Malaria, dehydration (HIV, diarrhoea) 
Rwanda Infections, trauma, toxins 
Ethiopia Malaria, surgical, acute glomerulonephritis 
Eritrea Infection 
Sudan Infection, toxins 
  
Southern Africa 
South Africa Infections (including HIV), toxins, pregnancy 
Mozambique Malaria, dehydration, obstetric 
Zimbabwe Prerenal (HIV), malaria, obstetric 
Zambia Malaria, obstetric 
Malawi Diarrhoeal disease, malaria, sepsis 
 
Reference: Naicker S et al. Epidemiology of acute kidney injury in Afr ica. Seminars in 
Nephrology. 2008;30(9):2051-8 (34)  
 
In South Africa, the causes of AKI have also transformed over the last few decades. An 
epidemiological study done in Durban in 1978 showed that the leading cause of AKI was 
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herbal toxin ingestion (38). A review approximately 10 years later showed that sepsis 
replaced toxin ingestion as the leading cause in South Africa (39). More recently, HIV 
infection has been reported as a major contributor of AKI (40).  Causes such as malaria, 
pregnancy induced kidney injury, glomerulonephritis (GN) and post surgical related AKI are 
still occurring albeit at a lower frequency than previously noted 
 
1.5.1 Acute tubular necrosis and acute kidney injury   
Acute tubular necrosis (ATN) and AKI are often mistakenly used interchangeably. ATN is a 
cause of AKI that is common in the hospitalized patient. In one study, ATN accounted for 
38% of cases with AKI for hospitalized, non intensive care unit (ICU) admissions (41) and 
rose to 76% of cases with ATN as their cause of renal failure when in ICU (41). ATN can be 
either ischaemic or toxin-related. Sustained pre-renal states are the most common factor for 
ischaemic ATN (41, 42) in both community-acquired and hospital-acquired kidney injury. 
Thus, fluid status and correction of these states early in management is pivotal in managing 
these patients and preventing significant morbidity and mortality. 
 
Sepsis is an extremely important and common cause for the development of ATN and 
ultimately AKI. In the ICU setting, sepsis is the leading cause of AKI in up to 51% of cases 
as reported in a French prospective study (43). Septicaemia can result from community-
acquired infections such as pneumonia, urinary tract infections, osteomyelitis, infective 
endocarditis as well as infections at other sites. It can also result from more virulent hospital 
acquired infections due to a vast array of organisms that include bacterial, fungal and viral 
infections. 
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The mechanisms and events resulting in renal dysfunction in sepsis are poorly understood. 
The systemic inflammatory response syndrome (SIRS) (44) which results in systemic 
hypotension with activation of vasoconstrictor hormones as well as the induction of nitric 
acid synthase and nitric oxide, which are potent vasodilators. All of which further 
compounds the poor perfusion state of the kidney and worsens the injury. Further release of 
cytokines, reactive oxygen species, and the activation of neutrophils by endotoxins all 
contribute to renal injury at the cellular level (45, 46). 
 
Other important considerations for the development of ATN include drugs and toxins. These 
are most often iatrogenic, as seen with contrast-induced nephropathy (47), drugs such as 
aminoglycosides, NSAIDs and ACE inhibitors in certain conditions (48, 49). Medical doctors 
need to be aware of these interactions and monitor their patients closely for these side 
effects particularly in the geriatric population.  
 
Other toxins are self inflicted and these include recreational drugs (50), herbal and 
traditional medications. The mechanisms for these effects on the kidney may either be 
direct nephrotoxicity or indirectly related (51). Herbal intoxication and traditional medications 
have gained favour particularly in the African (52) and Asian (53) continent. Many of the 
constituents are not laboratory tested and their safety is unknown. These agents have been 
linked predominantly with renal and liver toxicity. Traditional medication is a common 
practice in South Africa (54) and hence an important cause of AKI. This form of AKI is 
common and often difficult to treat, due to its rapid progression within the kidney as well as 
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its predilection for other vital organ systems. Early intervention is pivotal and often patients 
need to be admitted to ICU due to other comorbid dysfunction related to the toxin ingestion. 
 
1.5.2 Tubulo-interstitial nephritis and acute kidney injury   
Tubulo-interstitial nephritis (TIN) is a form of inflammation affecting the interstitium of the 
kidneys surrounding the tubules. This disease can be either acute, meaning it occurs 
suddenly, or chronic, meaning it is ongoing and eventually ends in chronic kidney failure. 
The major cause of TIN is often drug-related. A study in Boston in 2004 showed that 92% of 
TIN was caused by drugs.. This study also assessed the use of corticosteroids in the 
treatment of TIN and found no statistical benefit in its use (55).  
 
Most of the antibiotics including commonly prescribed ciprofloxicillin, penicillin, 
cephalosporins and vancomycin are associated with the development of TIN. Other 
commonly used drugs such as diuretics, NSAIDS, proton pump inhibitors, phenytoin, 
allupurinol and antivirals have also been noted as causative agents. The diagnosis may be 
confirmed by renal biopsy, however simple auxiliary investigations such as a urinary 
eosinophil count can suggest TIN but has poor sensitivity (56). 
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1.5.3. HIV and acute kidney injury   
HIV infection has become one of the major pandemics in the world. The Sub-Saharan 
region has been enormously impacted upon and carries the highest burden of this disease, 
including financial implications (57). South African medicine has seen a major 
transformation over the last 3 decades and the nephrology world is no exception.  
AKI is commonly observed in patients infected with the HIV (58).  The underlying causes of 
AKI in HIV are often multifactorial (59). These may range from the direct effect of HIV, 
opportunistic infections and medication related factors. Table 4 illustrates the classification 
of AKI in HIV positive patients (60). 
Table 4: Classification of AKI in HIV  
Pre-renal Causes 
 
Hypovolaemia: diarrhoea, nausea/vomiting, decreased oral intake 
Effective hypovolaemia: hypotension, sepsis, liver disease, 
hypoalbuminaemia(nephrotic syndrome, proteinuria, malnutrition) 
 
Intrinsic Renal Injury 
 
Acute tubular necrosis 
    Ischaemic: hypovolaemia, shock, sepsis, cardiopulmonary compromise 
    Nephrotoxic: medications, radio contrast 
    Rhabdomyolysis 
Parenchymal infection (mycobacterial, fungal, viral) 
Interstitial nephritis 
Haemolytic uraemic syndrome 
Glomerular disease: HIVAN, glomerulonephritis 
 
Post Renal Causes 
 
Intra-renal tubular obstruction: crystaluria from medications, tumour lysis syndrome 
Ureter or bladder obstruction: nephrolithiaisis, lymphadenopathy/tumour, fungus 
ball, blood clots, neurogenic bladder 
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Reference: Kalim et al –Acute kidney injury in HIV-infected patients. Seminars in Nephrology.2008;28(6):556-
62 (60). 
A French study published in 1999 biopsied HIV positive patients with renal failure, reported 
several different causes of AKI. These ranged from ATN, haemolytic uraemic syndrome, 
HIVAN and drug related nephrotoxicity (61).  
 
One of the most common renal entities caused by HIV is HIV-associated nephropathy 
(HIVAN) (62). This condition is characterized by severe proteinuria, rapid progression to 
renal insufficiency, and a morphologic pattern of collapsing focal segmental 
glomerulosclerosis (FSGS) on renal biopsy (63-65). Its progression to end stage renal 
disease is well known and hence makes up an increasingly large population of patients 
needing renal replacement therapy (RRT), posing a serious burden with regards to 
resources (57) . Although HIVAN is the predominant glomerular lesion in HIV infection, 
other reported glomerular lesions include HIV-immune complex kidney disease (HIVICK), 
IgA nephropathy, cryoglobulinaemia, amyloidosis, and a lupus-like immune complex 
glomelorulopathy (66, 67). While these are chronic glomerular conditions, they frequently 
present acutely with renal failure and need to be considered when evaluating patients with 
AKI. In the pre-antiretroviral therapy era, HIVAN was characterized by rapid progression to 
end stage renal disease (ESRD) and death.  Highly active antiretroviral therapy (HAART) 
has changed the natural course of this disease, highlighting the importance of prompt 
diagnosis and appropriate care (68). 
 
A study done at CHBAH, in 2006 showed that up to 27% of HIV positive patients with renal 
disease had   HIVAN. A further 21% were diagnosed with HIVICK (69). Another study done 
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in Kwazulu Natal during a similar timeframe also confirmed the high prevalence of HIVAN in 
South Africa (70).  
 
Treatment of HIVAN has also changed in the last 15 years. In one study, the rate of 
progression from the initial presentation to ESRD was 2.5 months in the pre-HAART 
era(71). The introduction of HAART has significantly slowed down this progression (71) 
(72).  Other treatment options include early institution of ACE- inhibitors (73, 74) as well as 
corticosteroids (75-77) which have been shown to be beneficial in certain groups. 
 
The most common cause of acute renal insufficiency is prerenal azotaemia from depletion 
of the intravascular volume. This can be a result of both “true” and “effective” depletion. 
Other common causes include direct damage to the renal tubules from both nephrotoxic 
medications and prolonged ischaemic processes that occur frequently in hospitalised 
patients. Injury to the tubulo-interstitium of the kidney may also result from allergic reactions 
to medications prescribed to patients. Deposition of crystals in the tubules, and rarely in the 
glomerular capillaries, will cause AKI in the setting of tumour lysis syndrome or during 
therapy with medications that result in crystal nephropathy. Finally, obstruction of the 
urinary system may cause post renal azotaemia in patients infected with HIV (60). 
 
With the advent of HAART, increased rates of kidney injury from drug related effects have 
been reported. Common nephrotoxic effects associated with HAART include crystal-
induced obstruction secondary to the use of protease inhibitors (mainly indinavir and 
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atazanavir), and proximal tubular damage related to the nucleoside reverse 
transcriptase inhibitors (NRTI), namely tenofovir (TDF). Acute kidney injury can 
occur following TDF-induced tubular dysfunction or as a result of severe 
mitochondrial dysfunction and lactic acidosis induced by this NRTI (78). Withdrawal of 
the drug leads to improvement of parameters (79), however support may be needed with 
RRT during the recovery phase. Importantly, the benefits of HAART outweigh the risks and 
hence HAART should not be avoided on this account but rather caution and close 
monitoring of renal parameters should be observed. 
 
HIV has increased the need for dialysis both in the acute as well as chronic setting (80). A 
study done in Cape Town showed that patients with HIV and AKI secondary to ATN and 
CD4 count of more than 200 have a good survival outcome (81). Risk factors for poorer 
outcome in HIV positive patients include co-existing Hepatitis C infection (82), black race, 
low CD 4 counts and pre existing chronic kidney disease (83). The Johannesburg study by 
Vachiat et al showed that outcomes in HIV positive and HIV negative patients were similar 
when offered dialysis and supportive care (40). 
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1.5.4 Malaria and acute kidney injury 
 
Malaria remains one of the most common diseases in the world, with a high burden in 
Africa. Four species of malaria affect humans, however, malaria infection caused by 
Plasmodium malariae or Plasmodium falciparum is recognized as an important cause of 
AKI and severe metabolic acidosis in complicated malaria (84).  
 
 
Figure 4: Reported cases of Malaria in 2011  
 
Reference: Kaiser Family Foundation. World Malaria Report 2012.www.GlobalHealthFacts.org, (85) 
 
 
The increasing incidence of malarial AKI represents a serious challenge in both South 
Africa and around the world. Most of South Africa, apart from areas in Kwazulu Natal, 
Limpopo and Mpumalanga are malaria free zones. The disease, however, still occurs in 
large numbers due to factors such as migrant labour, immigration from neighbouring states 
and the entity of taxi malaria. There has been a changing trend recently not only in the 
clinical manifestations, but also in the pattern of complications in malaria. Over a decade 
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ago, cerebral malaria was the predominant manifestation of severe malaria, whereas today 
the combination of jaundice and renal failure are more common (86). 
 
Acute kidney injury is seen most commonly in Plasmodium falciparum infection (87), 
however other malarial species can also induce renal injury. Since the precise mechanism 
of malarial AKI is not well known, several hypotheses have been made which include 
mechanical obstruction by infected erythrocytes, immune mediated glomerular and tubular 
pathology, fluid loss due to multiple mechanisms and alterations in the renal 
microcirculation (87).  
 
Malaria often has a deadly course in patients who are not treated early. Acute kidney injury 
requiring dialysis remains a common presentation in malaria (88) and frequently results in a 
poor outcome. In a study done in India in 2001, 92 % of patients with malaria and AKI went 
on to require dialysis (89). A recent review in Saudi Arabia in 2010, showed that 78% of 
patients with malaria and AKI required dialysis (90). These high rates are in accordance 
with other studies and show the large number of patients infected with malaria resulting in 
renal failure that requires dialysis. 
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1.5.5 Pregnancy and acute kidney injury 
 
Acute kidney injury poses a serious challenge when occurring in pregnancy. Acute kidney 
injury in pregnancy can be induced by any of the disorders leading to renal failure in 
the general population, such as ATN due to infection, glomerulonephritis related to 
lupus, or drug toxicity. There are, however, pregnancy complications characteristic of 
each trimester that can result in renal failure (91). 
 
In the first trimester, AKI occurs commonly due to hypovolaemic states secondary to the 
hyperemesis gravidarum or ATN secondary to septic abortions. Later in pregnancy, 
microangiopathic haemolytic diseases such as preeclampsia together with the HELLP 
syndrome and TTP-HUS are seen with drastic consequences (92, 93). These disease 
entities have specific characteristics and need to be diagnosed timeously and appropriate 
interventions instituted. 
 
Pregnancy-related AKI is a rare entity in developed countries but still occurs commonly in 
the developing world. A study done in 2013 in India showed that 11,5% of all AKI were 
pregnancy related. Sepsis, preeclampsia and haemorrhage were the major causes with a 
maternal mortality rate of 15% and a foetal mortality rate of 41.7% (94). 
 
A South African study published in 1995 showed that up to 16% of pregnancy related AKI 
required dialysis. The leading causes of AKI were preeclampsia and septic abortions (95). A 
prospective study carried out in an ICU setting, showed that as many as 25.8% of patients 
with eclampsia developed AKI and had a substantial mortality rate of 36.1% (96). 
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Pregnancy-related AKI remains a serious problem with high maternal and foetal mortality 
rates. 
 
1.5.6 Malignancy and acute kidney injury 
 
 
Certain malignancies such as multiple myeloma, genitourinary cancers and hepatocellular 
carcinomas have an increased risk and frequency of developing AKI (97). Multiple myeloma 
specifically causes various forms of kidney disease, however the majority of the 
consequences lead to chronic kidney disease (98). Acute kidney injury in multiple myeloma 
is often a result from factors such as dehydration, sepsis, hypercalcaemia, hyperuricaemia 
and chemotherapy related. The spectrum of renal lesions, typically chronic related, include 
cast nephropathy, amyloidosis (AL subtype), monoclonal immunoglobulin deposition 
disease and, less frequently, cryoglobulinaemic GN and proliferative GN (99). 
 
 
Tumour lysis syndrome is a constellation of biochemical and clinical abnormalities resulting 
from rapid and massive tumour cell death. It often occurs at the onset of treatment in 
particularly in tumours of high bulk burden. It is frequently associated with hyperuricaemia, 
hyperkalaemia, hyperphosphataemia, and secondary hypocalcaemia that may lead to 
serious clinical complications, including AKI and cardiac arrest (100). This effect is often 
noted in haematological malignancies but can occur with solid tumors particularly after 
chemotherapy.   
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Malignancies are also associated with GN. One of the theories for the cause is that a viral 
agent is responsible for both the cancer and the GN (101). The most common GN 
associated with malignancies, particularly haematological malignancies, is membranous 
GN.  One study showed that 10.7% of patients with a biopsy proven membranous GN had a 
concurrent malignancy (102). The rate of developing AKI requiring dialysis is less frequent 
and is associated with dehydration, sepsis,  hypercalcaemia and drug toxicity. 
 
 
Chemotherapeutic drugs in the treatment of cancer are often nephrotoxic and an important 
cause of AKI in malignancy as many are nephrotoxic (103) . Lastly, the bulk of the tumour 
itself can result in obstructive uropathy at the various anatomical levels of the genitourinary 
tract as commonly seen in cervical cancer, bladder and renal carcinoma. 
 
 
1.5.7 Other causes of acute kidney injury 
 
Other causes of AKI include crush syndrome with rhabdomyolysis, acute GN specifically 
poststreptoccal GN, autoimmune diseases such as  systemic lupus erythematosis (SLE) 
and scleroderma with acute renal crisis, microangiopathic haemolytic anaemias  and 
obstructive uropathy from any cause. 
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1.6. Treatment of acute kidney injury 
1.6.1 Supportive treatment  
 
The treatment modalities for AKI are largely supportive measures especially in the early 
stage of the disease. Supportive measures include the following: 
 
- Airway, breathing and circulation need to be firstly addressed and the patient 
adequately optimized 
- Blood pressure monitoring and appropriate intervention taken, particularly if the 
patient is severely hypotensive, the use of inotropes or fluids can be considered 
depending on the underlying cause of the decrease in blood pressure 
- The appropriate use of blood products 
- Assessing and addressing electrolyte derangements, with careful consideration 
for potassium, sodium, calcium and phosphate as these are often deranged with 
a high mortality if not adequately corrected 
- Maintaining acid/base balance 
- Close monitoring of urine output and hydration status of the patient 
 
A careful history, examination and directed investigations need to be done in order to 
ascertain the underlying cause of theAKI. Once the cause is identified, the main goal of 
treatment is to treat the underlying cause of AKI. For example; if sepsis from a bacterial 
organism is the culprit, adequate antibiotic therapy needs to be started in conjunction with 
supportive measures. 
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1.6.2 Dialysis 
 
Acute kidney injury poses a serious and often difficult complication of any underlying 
disease process. With cessation or decline in kidney function, nitrogenous waste 
accumulates and results in the severe symptoms seen in patients with kidney dysfunction. 
These include; uraemic bleeding, pericarditis, metabolic acidosis, encephalopathy, 
pulmonary oedema and life threatening electrolyte disturbances. In order to counteract 
these effects, dialysis needs to be instituted urgently.  
 
The concept of dialysis was born in the early 20th century by Dr. J Abel from John Hopkins 
Medical School in Baltimore. It was not until 1946, where a Dutchman, Dr. Willem Kolff 
achieved the breakthrough whereby a patient with AKI was dialysed and survived for the 
first time. Advances were then quickly made in this field and by 1960, the first long term 
chronic kidney patient began dialysis with success. Further improvements have been made 
and now various dialysis options are available with improved functionality and electrolyte 
control. 
 
The two main types of dialysis include peritoneal dialysis (PD) and haemodialysis (HD). 
Various factors ranging from both patient related and disease related are taken into 
consideration in deciding which modality to institute.  
 
Peritoneal dialysis can be an option in resource poor settings and is often used; it is less 
frequently utilised in AKI in South Africa at present. Peritoneal dialysis utilization has 
markedly declined for various reasons especially in countries with the resources to have all 
options at their disposal. The use of PD is precluded in some circumstances, such as after 
major abdominal surgery or severe trauma. Another drawback with PD is the inadequate 
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fluid volume control during dialysis. There are also concerns that the presence of dialysate 
in the peritoneal cavity may cause diaphragmatic splinting and result in higher ventilatory 
pressures in mechanically ventilated patients (104).  
 
A prospective study of 204 patients with AKI on PD was assessed in Brazil and showed that 
PD was effective in correction of metabolic acidosis and fluid control in a selected group of 
patients but had a high rate of mortality in the elderly and in severe sepsis (105). A 
systematic review in 2013 assessed the use of PD compared to HD and found no difference 
in outcomes between the two modalities (106); however more research is clearly needed to 
assess this option. Peritoneal dialysis is an established form of chronic RRT in our hospital 
and remains a favoured choice for many ambulatory patients due to the various advantages 
that it can offer. Peritonitis rates have been shown to be similar to that of developed 
countries as seen in a study conducted at CHBAH. (107) 
 
Haemodialysis remains the most commonly used modality in our setting at present. It allows 
for better and more accurate control and titration of electrolytes and fluid removal. The 
morbidity of HD is largely related to the insertion of the central venous catheter, occurence 
of deep vein thrombosis, cardiovascular instability and sepsis (108). Haemodialysis can be 
given intermittently or continuously. In ICU settings and in particular in patients with severe 
haemodynamic instability, continuous veno-venohaemo diafiltration is the preferred option. 
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1.7 Timing of dialysis 
 
The time for initiating dialysis remains controversial. Pre-dialysis blood urea and serum 
creatinine levels are not used in isolation. The pre-dialysis blood urea levels were assessed 
in a multicentre study. This study showed that initiating dialysis at high urea levels had a 
higher 60 day mortality rate (109). Urea levels are however affected by factors independent 
of kidney function. These include protein intake, catabolic state, gastrointestinal bleeding, 
pregnancy, chronic alcohol abuse and the use of corticosteroids (110).  
 
Serum creatinine levels closely relate to the current definition of AKI as it forms the basis of 
both the RIFLE and AKIN criteria (20). The pre-dialysis creatinine level is not routinely used 
as a measure for initiating dialysis on its own but rather in conjunction with other variables.  
The pre-dialysis serum creatinine was evaluated in a Cape Town study, which found a 
better outcome in HIV positive patients with AKI that were dialysed at lower pre-dialysis 
serum creatinine levels (81). Creatinine, however, is also influenced independently of the 
kidney and hence has limitations regarding its use in isolation, particularly in AKI and sepsis 
(111). 
  
1.8 Outcomes of acute kidney injury 
 
The major outcomes in AKI are renal recovery, death or need for chronic RRT. According to 
the RIFLE criteria, a diagnosis of chronic kidney disease may be made 3 months after the 
initial acute insult (16). Acute kidney injury is an independent poor prognostic marker for 
long term outcomes inclusive of mortality and development of CKD (112).  
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Renal recovery in AKI is defined as normalization of renal function within 3 months after the 
initial insult; however the majority of studies addressing renal recovery includes only 
critically ill patients that require acute dialysis and consider renal recovery as dialysis 
independency at hospital discharge (113). Higher rates of renal recovery have been 
documented in developed countries with rates of 56%, 61.8% and 68% respectively for 
renal recovery in patients with AKI (114-116). Renal recovery rates have been substantially 
lower in developing countries, as seen in India, where one study had a renal recovery rate 
of 43% (117). In South Africa, rates of renal recovery have been as low as 33.3% in HIV 
positive patients (81). 
 
 
 The need for chronic RRT is often a result of AKI. In one study, 15% of patients required 
chronic RRT after an acute insult (117). This is consistent with other literature which has 
rates of approximately 12.5% of patients with AKI requiring chronic RRT (118). 
 
Mortality rates of AKI vary from study to study. AKI independently increases mortality rates 
and has been shown to increase mortality by 5.5 fold (119). The mortality of AKI differs 
between ICU and non-ICU settings. Audits done in non-ICU patients both in developed and 
developing countries have mortality rates of between 24-46% (29, 117, 120). Patients that 
require dialysis within the ICU setting almost invariably have multiple other co-morbidities 
including respiratory, cardiac and liver failure. Renal failure requiring dialysis within an ICU 
setting has been shown to be a specific and independent risk factor for poorer prognosis. 
(121). A prospective multicentre study done in Austria analyzed over 17000 medical, 
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surgical and obstetric patients admitted to ICUs over a 2-year period. Close to 900 (5.3%) 
of these patients had renal failure requiring dialysis and this group showed a statistically 
significant higher hospital mortality rate and poorer outcomes compared to those patients 
with no renal dysfunction. Studies in Australia have shown mortality rates of as much as 
46.8 % (122) and 49.2% (123) amongst ICU patients requiring dialysis, compared to 
patients not requiring dialysis. 
 
1.9 Justification for study 
Limited data is available from South African hospitals over the last few years. The aim of 
this study is to audit the epidemiology of AKI that required dialysis. The causes of AKI in our 
population will be analysed as well as the outcomes of AKI at CHBAH. 
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1.10 Aims and Objectives  
1.10.1 Aims  
The aim of the study is to compile a profile and outcomes of all patients that were dialysed 
acutely at CHBAH over a two year period. 
 
1.10.2 Objectives  
The objectives include the following 
- to determine the demography 
- to determine the disease profile, including aetiology of primary renal disease and       
   chronic co morbidities. Co-infection with HIV, Hepatitis B and Hepatitis C will be reviewed. 
-to establish the pre dialysis blood urea and serum creatinine and relation to outcomes 
-to assess the aetiology of AKI and relation to outcomes 
-to compare the demography and outcomes in HIV positive and HIV negative patients with   
  AKI requiring  dialysis. 
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CHAPTER 2: METHODS 
 
2.1 Study Design 
 
A single centre retrospective review of patients that were acutely dialysed by the 
Nephrology Unit of CHBAH during the period of 1 July 2009 to 30 June 2011. 
 
Patients were selected from the electronic records of the CHBAH Renal Unit known as 
“BART”, which is an acronym for “Baragwanath Active Renal Tracking” system. A list was 
obtained from the electronic records and matched with records of patients that were acutely 
dialysed during this timeframe.  
 
2.1.1 Inclusion criteria   
The inclusion criteria included all patients who were: - greater than 14 years of age - presented to CHBAH between 1 July 2009 to 30 June 2011 - dialysed from the wards, Medical, Obstetrical and Burns High Care Units  
 
2.1.2 Exclusion criteria   
Exclusion criteria included all patients who: - were solely initiated on dialysis in the ICU  - had incomplete records  
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2.2 Ethics  
 
The University of the Witwatersrand Ethics Committee granted ethics approval 
unconditionally in May 2012 (clearance certificate M120412 – Appendix A). 
 
Confidentiality was maintained throughout the data collection process. A separate coding 
system known only to the primary investigator was used with the last 6 digits of the hospital 
number together with the first letter of the patient surname. 
 
2.3 Data collection and analysis 
 
The data collected, included the following (see Appendix B): 
 -Age 
 -Sex 
 -Race 
 -HIV status ± CD4 count ±ARV status 
 -Hepatitis B and C serology 
 -Pre-dialysis blood urea 
 -Pre-dialysis serum creatinine 
 -Cause of kidney injury 
 -Chronic co-morbidities (if any) 
 -Outcomes 
 
Causes of kidney injury were diagnosed based on clinical, biochemical, sonographical as 
well as biopsy in some cases and documented on the BART system. 
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The chronic comorbidities included hypertension, diabetes mellitus, malignancy and other. 
Hypertension and diabetes were defined in accordance with the South African Hypertension 
Guidelines 2011 and the SEMDSA Diabetic Guidelines 2012 . 
 
A computer program known as REDCap was used to capture and enter the data. REDCap 
is a tool that is Witwatersrand University-approved and users need to be registered with a 
Witwatersrand University staff or student card. This effective tool allows the researcher to 
capture data on a web designed data collection sheet that can be accessed via mobile 
devices such as a smartphone or tablet. This ensures a paperless data collection process. 
The REDCap service is a secure network whereby only the user with a secure username 
and password obtains access. This also allows for a backup to be made on a cloud server. 
The data collection sheet was electronically designed on REDCap and data was then 
successfully captured. See Appendix A for data collection sheet. 
 
Majority of the data, including blood results, was obtained directly from the BART system 
however outstanding blood results such as HIV, Hepatitis B, C and pre-dialysis blood urea 
and serum creatinine were obtained from the NHLS blood tracking system using the 
patients’ hospital numbers. The demographical data were obtained and placed on REDCap. 
The causes of the kidney injury were documented in the electronic records on the BART 
system. This was usually entered by the registrar/medical officer at the time of the initial 
consultation but would be invariably checked by a senior nephrologist. This helped to limit 
the misdiagnoses that may occur during the capturing done on the BART system. Once the 
REDCap database was completed, verification of data was done using tools readily 
available within the REDCap software. The data was then exported from REDCap into 
Microsoft Excel.  
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All descriptive statistics such as means, medians, frequencies, percentages as well as 
standard deviations and interquartile ranges were obtained from the Microsoft Excel 
spreadsheet. Graphs such as pie charts, frequency distribution tables and contingency 
tables were drawn from Microsoft Excel. The remaining outcomes that needed to be 
assessed were done with the help of Dr. A Bentley and Graph Pad. Statistical tools such as 
Chi-square, Fisher exact, ANOVA and Tukey-Kramer Multiple comparison tests were used. 
 
Statistical significance was measured at the 5% level (p value of<0.05) for statistical 
significance. 
 
2.4 Definitions of outcomes measured 
 
The outcomes measured in this review were as follows: - Renal recovery: Normalisation of renal function and independence of dialysis. - Transfer to chronic renal replacement therapy (RRT):  after initiation of 
dialysis, there is failure of full recovery and hence the need for transfer to the 
chronic programme for continuation of dialysis. The form of dialysis could be 
haemodialysis or peritoneal dialysis. The type of renal replacement therapy was 
not assessed. - Transfer to renal outpatients (ROPD): The cessation of dialysis after it was 
noted that the patient was a poor candidate for continuation of dialysis, or does 
not fulfill criteria for acceptance for chronic renal replacement therapy. This group 
also comprises those patients that did not regain full renal function but dialysis 
was not continued for various reasons that were not reviewed. 
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- Death: The patient was initiated on dialysis and demised - Loss to follow up: Unknown outcome/loss to follow up - Poorer Outcomes: defined as those patients that fail to regain kidney function 
and include the “transfer to chronic RRT’, “transfer to ROPD’ and “death” groups. 
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CHAPTER 3: RESULTS 
 
3.1 All Patients 
3.1.1 Demography and clinical data 
 
 
 
The two-year audit comprised of all patients that were acutely dialysed at CHBAH from 1 
July 2009 to 30 June 2011. A total of 340 patients were reviewed but only 324 were 
analysed. The remaining 16 patients were excluded, as minimal records regarding their 
diagnosis and demographic data were obtainable. 
 
 
 
Table 5: Demography of patients that underwent acute dialysis  
 
Number 324 
Age (in years) 
[mean±SD] 40±13 
Gender -  Males 184(57%) 
              -  Females 140(43%) 
Race – Black 299(92.3%) 
          - Coloured 12(3.7%) 
          - White 8(2.5%) 
          - Indian 5(1.5%) 
 
 
 
 
The demographics of all 324 patients are presented in Table 5. The mean age was 40 ± 13 
years; 184 patients (57%) of the cohort were male; 299 patients (92.3%) comprised of Black 
race, followed by Whites (2.5%), Coloureds (3.7%) and Indians (1.5%) as depicted in Figure 
5 and 6. 
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Figure 5:Race of patients on acute dialysis (N=324) 
 
 
 
 
Figure 6: Gender of patients on acute dialysis (N=324) 
 
 
 
 
3.1.2 HIV, Hepatitis B and Hepatitis C status 
 
 
Figure 7: HIV status of patients on acute dialysis 
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The HIV status of patients undergoing acute dialysis was analyzed in the cohort and 
presented in Figure 7. HIV positivity accounted for 83 patients (26%); in 20 patients (6%), 
the HIV status was unknown. 
 
 
 
Figure 8: Hepatitis B serology of patients on acute dialysis 
 
 
 
Hepatitis B serology is presented in Figure 8; 13 patients (4%) were Hepatitis B positive and 
230 patients (71%) had negative Hepatitis B serology. A quarter of the cohort had unknown 
Hepatitis B status.  Hepatitis B co-infection with HIV occurred in 3 of the 83 patients (3.6%) . 
 
Figure 9: Hepatitis C serology of patients on acute dialysis 
 
 
Six patients (2%) were found to be Hepatitis C positive (Figure 9). The majority of the 
patients were Hepatitis C negative (70%) however 28% of the cohort had an unknown 
Hepatitis C status. Co infection of Hepatitis C and HIV occurred in 1 patient (1.2%)  
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3.1.3 Decompensated Chronic Kidney Disease  
 
Figure 10: Decompensated chronic kidney disease (N=126) 
 
 
 
A large proportion of the patients had evidence of underlying chronic kidney disease and 
subsequently developed an acute on chronic deterioration of their renal function, resulting in 
the institution of acute dialysis. This group comprised of 126 patients (39%) of the cohort. 
Hypertension accounted for 66% of these patients, whilst diabetes mellitus was noted in 
20% of the patients.  At the time of institution of dialysis, 75 out of the 83 (90%) 
hypertensive patients were receiving treatment for hypertension. Sixteen (19%) of the 
hypertensive patients were hypertensive for more than 5 years. 
 
Diabetes occurred in 25 patients. The types of diabetes were not recorded. Majority of 
diabetic patients were on treatment, (24 of the 25,96%), of which 12 (48%) were on 
treatment for more than 5 years. Eleven patients (9%) had both diabetes and hypertension. 
 
20% 
66% 
6% 8% 
Diabetic Hypertension Other Unknown 
 41 
The “other” group comprised of the following; Primary oxaluria (1 patient), Polycystic kidney 
disease (3 patients), dilated cardiomyopathy (2 patients) and chronic liver disease (1 
patient) 
 
3.1.4 Discipline of referral  
 
Referral from the medical wards accounted for 254 patients (78%). The surgical wards and 
obstetrics wards accounted for 38 patients (12.5%) and 26 patients (8%) respectively. Six 
patients had an unknown ward of referral. 
 
 
 
3.1.5 Causes of kidney injury 
 
 
Figure 11: Causes of kidney injury 
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Table 6: Causes of ATN 
Causes Number 
Sepsis 106 
Toxin/Herbal 10 
Pancreatitis 5 
Contrast 
induced  3 
 
 
Figure 11 depicts the causes of kidney injury in the 324 patients that were reviewed. 
Patients may have had more than one cause for the AKI. 
 
Decompensated chronic kidney disease accounted for 126 patients (38.9%). ATN occurred 
in 124 patients (38.3%). The underlying causes of ATN are presented in Table 5. Sepsis, 
the second leading cause of renal failure requiring dialysis accounted for 106 (32.4%) of 
these patients, whilst herbal intoxication occurred in 10 patients. This group of patients were 
known to have taken a herbal/traditional medication that resulted in the insult. Pancreatitis 
with associated kidney damage occurred in 5 patients, with 3 patients having ATN 
secondary to contrast induced nephropathy. 
 
 
HIV related kidney disease affected 44 patients (13.6%). 7 of these patients (16%) had a 
kidney biopsy done that showed HIV associated nephropathy. The remaining 84% were 
diagnosed with HIV related kidney disease based on HIV status, sonar features of 
hyperechoic ± enlarged kidney sizes, presence of proteinuria and clinical features of 
proteinuria and renal dysfunction. Other causes of AKI in HIV positive patients are tabulated 
in Table 10, with most HIV positive patients having more than one cause for the AKI. 
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Glomerular disease occurred in 24 patients (7.4%). These included both primary 
glomerolunephritis (G)N (10 patients) and secondary GN (14 patients).  The primary GN 
was diagnosed on biopsy in 8 out of the 10 patients: Membraneous nephropathy (2 
patients), cresenteric GN (2 patients), Membroproliferative GN (2 patients) and Focal 
segmental glomerulosclerosis (2 patients). The remaining 2 patients had a diagnosis of 
Primary GN noted on the system but details of the biopsies were not found in records.  All 
patients with secondary GN were noted to have SLE. 
 
 
Pregnancy-related kidney injury accounted for 24 patients (7.4%) that underwent acute 
dialysis. 19 patients (5.9%) were dialysed for acute kidney injury secondary to Falciparum 
malaria. 
 
Obstructive uropathy accounted for 12 patients (3.7%) and malignancy, with associated 
kidney injury accounted for 11 patients (3.4%). The types of malignancies are presented in 
Table 7.  
 
Table 7: Type of malignancies  
Malignancy Number 
Non Hodgkins lymphoma 3 
Multiple myeloma 2 
Acute myeloid leukemia 1 
Prostate cancer 2 
Primary brain tumour 1 
Renal cell carcinoma 2 
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Malignant hypertension, rhabdomyolysis and hypotensive states accounted for 10 patients 
each (3.1%). The hypotensive states included patients with cardiomyopathies, pulmonary 
embolus and valvular heart disease. 
 
3.2 HIV infection and acute kidney injury  
3.2.1 Demography and clinical data of HIV positive patients 
 
Table 8: Demography and clinical data for HIV positive patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV positivity accounted for 26% of patients presenting for acute dialysis. The average age 
of these patients was 39 ± 11 years; male to female ratio was approximately 1:1(Table 8). 
 
Number 83 
Gender – Male   [n(%)] 41(49%) 
               - Female [n(%)] 42(51%) 
  
Age (years) 39±11 
  
CD4 count (cells/μl)  [mean±IQR] 153(4-621) 
  
Hepatitis B Positive  [n(%)] 3 (3.6%) 
   
Hepatitis C Positive  [n(%)] 1(1.2%) 
  
On ARVS   [n(%)] 16 (19%) 
Not on ARVS  [n(%)] 51 (62%) 
Unknown ARV status  [n(%)]  16 (19%) 
  
Pre dialysis blood urea level (mmol/l)  [mean±SD] 43±21 
  
Pre-dialysis serum creatinine (μmol/l)  [mean±SD] 1053±581 
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Co-infection with both Hepatitis B and C occurred infrequently; however >35% of patients 
had unknown Hepatitis B and C serology. 
 
The median CD4 count was 153 cells/μl (IQR 4 to 621 cells/μl). The median CD4 count of 
patients that were on ARVs was 240 cells/μl (IQR 106-621 cells/μl). The CD4 counts of the 
51 patients not on ARVs were much lower, with a median of 83 cells/μl (IQR 4-572 cells/μl 
(Table 9), 
 
Table 9: Median CD4 counts related to ARV status 
 On ARVs (N=16) Not on ARVs (N=51) 
CD4 ± IQR (cells/μl) 240  (106-621) 83   (4-572) 
 
 
16 patients (19%) were on ARVs at time of presentation, with 51 patients (62%) not on any 
treatment. 
 
The average pre-dialysis blood urea and serum creatinine was 43±21 mmol/l and 1053±581 
μmol/l respectively. 
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3.2.2 Causes of kidney injury in HIV positive patients 
 
Table 10: Causes of kidney injury in HIV positive and HIV negative patients 
 
HIV 
Positive 
(N=83) 
HIV 
Negative 
(N=221) 
Decompensated chronic  
kidney disease 7 116 
ATN 53 63 
HIV related kidney disease 44 0 
Glomerulonephritis* 2 21 
Pregnancy 7 16 
Malaria 13 5 
Obstructive Uropathy 0 12 
Malignancy 4 6 
Other 4 7 
Rhabdomylosis 1 5 
Malignant hypertension 0 10 
Hypotension 3 6 
Drugs 4 5 
Unknown 0 6 
Severe Metabolic acidosis 0 3 
HUS 1 0 
* Primary GN accounted for 10 patients and secondary GN occurred in 14 patients 
 
The disease spectrum of HIV and its impact on the causes of kidney injury resulting in the 
need of acute dialysis is shown in Table 10. All causes in both the HIV positive group and 
negative group are noted, however the HIV unknown group was not analysed. Primary 
glomerulonephritis, obstructive uropathy, contrast induced nephropathy and malignant 
hypertension occurred only in the HIV negative group. 
 
 
Table 11: Top 5 causes of kidney injury in HIV positive patients  
ATN 53 
HIV related kidney disease 44 
Malaria 13 
Pregnancy 7 
Decompensated kidney 
disease 7 
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The major cause of AKI in HIV positive patients is ATN, occurring in 64%, compared to HIV 
negative patients with only 29% being affected with ATN (Table 10 and 11). Patients may 
have had more than one cause for the AKI. 
 
Malaria was the third most common cause of AKI amongst HIV positive individuals. 16% of 
HIV positive patients that were acutely dialysed had malaria.  
 
Pregnancy-related kidney injury had similar frequencies in the two groups whilst there was 
a marked difference in the decompensated chronic kidney disease group. HIV positive 
patients only accounted for 8% compared to the HIV negative group with greater than 50% 
of patients with decompensated chronic kidney disease. 
 
 
3.3 Demography and clinical data of patients with malaria 
 
 
Table 12: Demography and clinical data of patients with malaria  
Number 19 
Gender – Male 17 (89%) 
               - Female 2 (11%) 
  
Age (years) 39±12 
  
HIV positive 13 (68%) 
  
Pre-dialysis blood urea (mmol/l) 41±12 
  
Pre-dialysis serum creatinine (μmol/l) 848±428 
 
 
 
 
Nineteen patients (6%) requiring acute dialysis at CHBAH had Falciparum malaria. Males 
accounted for 89% (Table 12). The mean age was 39 ±12 years.  
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Majority of patients (68%) were co-infected with HIV. The average pre-dialysis blood urea 
was 41 mmol/l and the pre-dialysis serum creatinine was 848 μmol/l. 
 
3.4 Demography and clinical data in pregnancy-related kidney injury 
 
 
Table 13: Demography and clinical data of patients with pregnancy-related kidney injury  
Number 24 
Age (years) 28±7 
  
HIV positive 7 (29%) 
  
Pre-dialysis blood urea (mmol/l) 19±7 
  
Pre-dialysis serum creatinine (μmol/l) 
 
499±112 
 
 
 
 
 
Pregnancy-related kidney injury accounted for 24 patients (7%) of the cohort. The mean 
age was 28±7 years. HIV positivity occurred in 29% of pregnant females (Table 13). 
The pre-dialysis blood urea and pre-dialysis serum creatinine was 19±7 mmol/l and 
499±112 μmol/l respectively. 
 
The underlying cause of the pregnancy-related kidney injury is illustrated in Table 14. 
Table 14: Causes of pregnancy-related kidney injury 
Pregnancy related condition Number 
Pre-eclampsia/HELLP 
Syndrome 18 
Eclampsia 2 
Abruptio placentae 3 
Post partum haemorhage 1 
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3.5 Outcomes 
 
The outcomes assessed in this study group include the following: - Renal recovery - Transfer to chronic renal replacement therapy - Transfer to Renal Outpatient Department - Death - Loss to follow up 
 
3.5.1 Pre dialysis blood urea and outcomes 
 
The pre-dialysis blood urea recorded was the last documented blood urea prior to 
commencement of dialysis. The mean was calculated and compared to each outcome. 
 
 
Table 15: Pre-dialysis blood urea (mmol/l) in all patients 
 
Renal 
recovery 
 
 
Transfer 
to  
chronic 
RRT 
Transfer 
to ROPD 
 
 
Death 
 
 
 
Loss to 
follow up 
 
 
ALL Patients*(N=324) 34±19 49±20 51±22 45±23 24±10 
HIV +(N=83) 35±22 30±24 49±17 48±21  
HIV- (N=221) 34±18 50±19 53±24 44±23 27±6 
Malaria (N=19) 39±25     
Pregnancy (N=24) 20±6     
*p value <0.0001 
 
 
 
The mean pre–dialysis blood urea for all patients are presented for each outcome in Table 
15. Pregnancy-related kidney injury had the lowest pre-dialysis blood urea level of 20 
mmol/l compared to all patients with a blood urea of 34mmol/l. Lower pre-dialysis blood 
urea levels were observed in the renal recovery for all patient categories compared to 
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higher levels seen in the other outcomes that included transfer to chronic RRT, transfer to 
ROPD and Death. (p value <0.0001). ANOVA test was used. 
 
Initiating dialysis at higher blood urea levels was associated with a poorer outcome in all 
patients (P<0.0001) 
 
 
 
3.5.2 Pre-dialysis serum creatinine levels and outcomes 
 
The pre-dialysis serum creatinine levels of each group were compared to outcomes as 
depicted in Table 16. 
 
 
Table 16: Pre-dialysis serum creatinine levels (μmol/l) for all patients 
 
Renal 
recovery 
 
 
Transfer 
to  
chronic 
RRT 
Transfer 
to ROPD 
 
 
Death 
 
 
 
Loss to 
follow up 
 
 
ALL Patients *(N=324) 804±467 1602±732 1335±634 1108±700 801±376 
HIV +(N=83) 805±422 1010±794 1424±704 1046±490  
HIV- (N=221) 811±495 1627±725 1316±605 1188±824 867±380 
Malaria (N=19) 831±403     
Pregnancy (N=24) 501±116     
*P value<0.001 
 
 
The renal recovery group had a similar pre-dialysis serum creatinine of between 804-831 
μmol/l for all patients except for the pregnancy induced kidney injury group. This group had 
much lower serum creatinines with an average of 501 μmol/l. There was statistical 
significance for renal recovery at lower pre-dialysis serum creatinine levels compared to the 
other outcomes (p value <0.0001). 
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3.5.3 Causes of acute kidney injury and outcomes 
 
 
 
Table 17: Outcomes in all patients (N=324) 
Outcome Number 
Renal Recovery 98 (31%) 
Transfer to chronic 
RRT 75 (23%) 
Transfer to ROPD 70 (21.6%) 
Death 76 (23%) 
Loss to follow up 5(1.4%) 
 
 
 
The outcomes of all 324 patients analyzed are illustrated in Table 17. 98 (31%) patients had 
renal recovery; 23 % of patients were transferred to chronic RRT and offered chronic 
dialysis; 21.6% of patients were transferred to renal outpatients with cessation of their 
dialysis; 76 patients (23%) had demised. 
 
Table 18: Outcomes of the leading causes of kidney injury 
  
Renal 
Recovery 
 
 
Transfer 
to 
chronic 
RRT 
Transfer 
to ROPD 
 
 
Death 
 
 
 
Loss to 
follow 
up 
 
Decompensated CKD(N=126) 2(1.5%) 66(52%) 37(30%) 19(15%) 2(1.5%) 
ATN (N=124) 39(31.5%) 4(3.2%) 27(21.8%) 52(41.9%) 2(1.6%) 
HIV related kidney 
disease(N=44) 5 (11%) 2(5%) 18(41%) 19(43%) 0(0%) 
Glomerulonephritis(N=24) 2(8.3%) 7(29.2%) 6(25%) 8(33.3%) 0(0%) 
Pregnancy (N=24) 22(92%) 0(0%) 1(4%) 0(0%) 1(4%) 
Malaria(N=19) 15(79%) 0(0%) 3(16%) 1(5%) 0(0%) 
Obstructive Uropathy (N=12) 2(17%) 2(9.5%) 7(58%) 2(9.5%) 0(0%) 
 
 
The outcomes of the leading causes of AKI in all patients are illustrated in Table 18. The 
decompensated CKD group had over 50% of patients transferred to the chronic RRT and 
continuation of dialysis; 15% of this group demised. 41.9% of the ATN group patients 
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demised, with 31.5% obtaining renal recovery. 11% of patients with HIV related kidney 
disease had renal recovery whilst 43% demised. 
  
The glomerular disease group had 8.3% recovery, with one third of this group demising and  
29.2% were placed on the chronic renal replacement program.  The highest rate of renal 
recovery was the pregnancy related kidney injury group, with 92% of patients obtaining 
renal recovery. Seventy-nine percent of patients with malaria and kidney injury had renal 
recovery. The largest proportion of patients that transferred to ROPD and had dialysis 
discontinued despite failing to recover renal function comprised those with obstructive 
uropathy, accounting for 58% of this group. This group comprised predominantly of older 
patients with chronic co-morbidities and malignancies. 
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3.5.4 HIV infection and outcomes 
 
 
3.5.4.1 Outcomes in HIV positive patients   
Figure 12: Outcomes in HIV positive patients (N=83) 
 
 
 
 
Figure 12 illustrates the outcomes of HIV positive individuals. 30 patients (36%) had renal 
recovery, with a similar proportion demising [28 patients (34%)]. 
 
 
Table 19: Outcomes in HIV positive vs HIV negative patients 
 
Renal 
Recovery 
 
 
Transfer 
to 
chronic 
RRT 
Transfer 
to ROPD 
 
 
Death 
 
 
 
Loss to 
follow up 
 
 
HIV Positive (N=83) 30 (36%) 3 (4%) 21 (25%) 28 (34%) 1 (1%) 
HIV Negative (N=221) 58 (26%) 71 (32%) 46 (21%) 42 (19%) 4 (2%) 
Chi2 28.3; dF=3; p value<0.0001  
 
A comparison of HIV positive and negative individuals is shown in Table 19. Renal recovery 
occurred in 58 patients (26%) of HIV negative patients; HIV positive patients had a better 
rate of renal recovery with 36% of HIV positive patients showing renal recovery (p<0.0001). 
Death as an outcome in both groups showed rates of 19% in HIV negative group and 34% 
30 
3 
21 
28 
1 Renal Recovery T/F to RRT T/F to ROPD Death Unknown 
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in HIV positive group (p<0.0001). A small proportion of HIV positive patients (4%) was 
transferred to the chronic RRT compared to 71 patients (32%) in the HIV negative group. 
There was a statistical difference between outcomes in these two groups (p <0.0001). 
Twenty-one percent of HIV negative patients were transferred to ROPD and cessation of 
their dialysis compared to 25% of HIV positive individuals. 
 
3.5.4.2 Outcomes in HIV positive patients based on CD4 counts   
Figure 13: Outcomes in HIV positive patients based on CD4 count 
 
Chi2=4.77; dF=3;P=0.1894 
 
 
 
The CD4 counts of HIV positive individuals were noted with 7 of the 83 patients having an 
unknown CD4 count. There were 50 patients that had a CD4 count of less than 200 and 26 
patients had a CD4 count greater than 200.  Fifteen patients (30%) with a CD4 count of less 
than 200 had renal recovery compared with 12 patients (46%) in the CD4 count greater 
than 200. 19 patients (38%) with lower CD4 demised compared to 7 patients (26%) in the 
higher CD4 count group. There was no statistical significance between the two groups for 
all outcomes (p value=0.1894). 
15 
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3.5.4.3 Outcomes in HIV positive patients based on ARV status 
 
 
Figure 14: Outcomes in HIV positive patients based on ARV status
 
P value=0.5857 
 
 
Antiretrovirals have become the mainstay and most effective treatment of choice in HIV 
infection. Sixteen patients (19%) were on ARVS at the time of diagnosis of the renal injury, 
with only 3 (18.5%) of these patients showing recovery and 6 (37.5%) demised. The 
majority of patients were not on ARVS (51 patients, 61%). Renal recovery occurred in 19 
patients (37%); however a significant proportion demised (33%). There were no statistical 
differences of all outcomes between the two groups (p value=0.5857), probably due to the 
small sample size. 
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CHAPTER 4: DISCUSSION  
4.1 Demography of patients presenting for acute dialysis 
 
South Africa has a diverse population with various social and political influences that have 
changed patterns of disease and patient profiles within our hospitals. The mean age of 
presentation was 40 ± 13 years. The age of presentation is consistent with other developing 
countries. A retrospective review of patients with AKI in a North Indian tertiary institution 
showed that the mean age of presentation of AKI was 39 ±14 years (117). A similar review 
done in Saudi Arabia had a mean age of 33.7 ± 10.1 years(124). This is in contrast to first 
world countries. An epidemiological study of AKI done in Madrid, Spain had an average age 
of 64 ± 17 years (28). A United Kingdom based study had over 90% of its cohort being 
greater than 70 years of age (125). The large difference in age is directly related to the 
various patterns of disease that is seen between first world and third world countries. This is 
in contrast to the disease profile that occurs in developing countries of the world. Factors 
such as infective causes and pregnancy-related kidney injury also occur in increasing 
frequencies within the developing countries, resulting in the large discrepancy between the 
age groups. 
 
 
Males accounted for 57% of the cohort. This closely resembles the findings of patients with 
HIV and AKI at a Johannesburg hospital; Vachiat et al had a 56% male predominance in his 
cohort (40). 
 
Race has been a major discriminating factor in the history of South Africa. Various 
important factors over the last 100 years have affected the epidemiology of disease in 
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South Africa. CHBAH is  situated in the heart of Soweto, a bustling area with a population of 
more than 1.5 million residents, of which the predominant race is black African. This large 
population accounts for the predominant race that feeds into the CHBAH drainage areas, 
with 92.3% of patients being black African. 
 
 
Infective disease screening prior to dialysis is often done, in particular HIV, hepatitis B and 
hepatitis C. Eighty-three patients (26%) were HIV positive; 4% and 2% of patients had 
confirmed serology for hepatitis B and hepatitis C respectively; 6 % of the cohort had  
unknown HIV status,  whilst the hepatitis B and hepatitis C unknown rates were much larger 
with more than 25% of patients not being tested for these infective diseases.  
 
 
The prevalence of hepatitis B infection is estimated to be around 1% in South African urban 
areas (126). Our study noted a 4% rate of hepatitis B infection. A study conducted in 
Johannesburg clinics found a 5% rate of hepatitis B co infection with HIV (127). Three 
patients (3.6%) with HIV had co infection with hepatitis B.  
 
 
The world wide incidence of hepatitis C is around 2-3% (128). Similar incidence is noted in 
our study with 2% of patients having Hepatitis C. The impact of HIV co infection was 
demonstrated by the CAESAR study. This multicentre study showed varying rates of HIV 
and hepatitis C co infection worldwide, with South Africa having a co-infection rate of 1.9% 
compared to rates as high as 48% in countries such as Italy (129). The HIV and  
hepatitis C co infection rate in our study was 1.2%, similar to the CAESEAR study figures. 
 58 
4.2 Decompensated chronic kidney disease and co-morbidities 
 
A large proportion of patients, 126 patients (39%), had an underlying chronic component to 
their decline in kidney function, with urgent need for acute dialysis. This group was defined 
as those patients that had a documented history or evidence of an underlying chronic 
reason for their kidney dysfunction and presented with an acute insult that resulted in rapid 
decline and need for acute dialysis. 
 
 
The leading cause of underlying chronic co morbidity was hypertension. Sixty-six percent of 
patients in this group were diagnosed with hypertension and 90% of hypertensive patients 
were receiving treatment; 16 (19%) of the hypertensive patients were on treatment for more 
than 5 years. Diabetes mellitus accounted for a further 20% of patients in this group; 48% of 
these patients were on diabetic medication, either insulin or oral hypoglycaemics for more 
than 5 years. The decompensated chronic kidney group were all included in the analysis as 
they had an acute component at the time of initiation of dialysis. 
 
4.3 Causes of acute kidney injury 
 
The causes of AKI are often multifactorial with various aetiologies occurring in a single 
patient. Renal biopsy may be needed to give a definitive diagnosis. The underlying cause of 
kidney injury is often established on the basis of an adequate history and clinical features. It 
is supported by auxiliary investigations such as blood tests, radiological investigations and 
in some circumstances, more invasive procedures such as a biopsy.  The causes of kidney 
injury found in our cohort are presented in Figure 11. 
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The majority of the patients (78%) with AKI requiring dialysis were referred from the medical 
wards. This is consistent with the audit done in India where medical patients accounted for 
77% (117). Another audit carried out in the Himalayan region had close to 86% medical 
referrals (130) The study by Vachiat et al had 81% of patients referred from medical wards 
(40). Surgical and obstetric referrals for AKI and dialysis accounted for 12% and 8% 
respectively. Likely reasons for this large discrepancy include a selection bias against 
surgical and obstetrical referrals a large proportion of these patients present with pre renal 
dysfunction that can be treated conservatively, thus obviating the need for dialysis. 
 
 
Seedat et al reviewed the causes of kidney injury in a South African population in 1978. 
This study showed that the leading cause of AKI was nephrotoxins (38). A subsequent audit 
a decade later by the same author showed that sepsis had replaced nephrotoxins as a 
leading cause of AKI (39). These findings are consistent with our cohort as sepsis 
accounted for 32.4% of AKI. AKI due to ATN was documented in 124 patients (38.2%). The 
underlying causes of ATN included sepsis (106 patients), toxins/herbal ingestion (10 
patients), pancreatitis (5 patients)  and contrast induced nephropathy (3 patients). Higher 
rates of ATN as a cause of AKI were found in the Madrid study that showed ATN accounted 
for 45% of their causes of AKI (29).The leading cause of ATN in our study was sepsis, 
accounting for 32.4% of the total study group. Sepsis accounted for approximately 50% of 
cases in the Cape Town based audit (81), whilst in India, sepsis accounted for 33.3%  
(130). 
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Malaria complicated by AKI with subsequent need for acute dialysis accounted for 19 
patients (6%). Malaria with co infection of HIV occurred as the third most common cause of 
kidney injury in HIV positive patients, resulting in 16% of HIV positive patients needing to be 
dialysed. Malaria remains a common cause of AKI particularly in most of Africa as noted by 
Naicker et al in an epidemiological review published in 2008 (34).  
 
 
Acute kidney injury in pregnancy is still a major problem in developing countries. 
Pregnancy-related kidney injury accounted for 24 patients (7.4%) of our cohort. This 
included eclampsia (2 patients), pre eclampsia (18 patients), abruptio placentae (3 
patients), and post partum haemorhage (1 patient). This rate of 7.4% has substantially 
decreased from previous audits done in South Africa which showed that pregnancy-related 
AKI accounted for 16% of all AKI requiring dialysis (95). Improved antenatal screening, 
quicker delivery of patients and better obstetric intervention may be responsible for this 
reduction in frequency over the last 20 years. The rates of AKI in pregnancy in centres in 
India range from 11-14.5% (94, 117). One-third of all pregnancy-related AKI were HIV 
positive, with pre eclampsia as the predominant cause of AKI in this group. 
 
 
Obstructive uropathy occurred in 12 patients (3.7%). This is substantially lower than first 
world countries where rates of 10% noted in Spain (29). The likely reason for this marked 
discrepency includes most notably the established geriatric population in the first world 
nations, with obstructive uropathy occurring more commonly within this group. The elderly 
patients and in particularly those with malignancies may be overlooked for dialysis and 
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excluded from the public sector dialysis programmes, thus decreasing the frequency of 
these patients being acutely dialysed. 
 
 
The incidence of rhabdomylosis secondary to trauma, also referred to as “sjambok injury” 
has increased in South Africa (131). 3 % of the patients dialysed had rhabdomylosis 
complicated by AKI requiring dialysis. All of the 10 patients had developed rhabdomylosis 
secondary to violent injury and were admitted to the trauma unit. 
 
 
Nine patients developed AKI requiring dialysis secondary to drug interactions. 2 of these 
patients had biopsy confirmed tubulo-interstitial nephritis; 3 of the patients were HIV positive 
on Tenofovir ; 2 of the 9 patients had lithium overdose and required dialysis subsequently. 
The offending drug was unknown in 4 patients. 
 
 
Malignancy and subsequent initiation of dialysis occurred in 11 patients. 6 of these patients 
were HIV negative whilst 4 were HIV positive and 1 had an unknown HIV status. The 
malignancies encountered included Non Hodgkins Lymphoma (3 patients), Multiple 
Myeloma (2 patients), Acute Myeloid leukemia (1 patient), Prostate cancer (2 patients), 
Primary Brain tumour (1 patient) and Renal cell carcinoma (2 patients). 
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4.4 HIV and kidney injury – Demography and clinical data 
 
HIV positivity accounted for 83 patients (26%) of our cohort. The mean age of presentation 
was 39 ± 11 years. This is consistent with the study conducted in Charlotte Maxeke 
Academic Hospital in Johannesburg which had a mean age of 38±9 years (40). There were 
no gender differences within the HIV positive group. The median CD4 count for all patients 
with HIV was 153 with a range of 4 to 621, consistent with the Johannesburg study that had 
a median CD4 count of 135. Hepatitis B and C co infection with HIV occurred in 3.6% and 
1.2% of the HIV positive group respectively. 
 
 
Antiretrovirals have become the mainstay of HIV management, both around the world and 
in South Africa. Of the 83 patients with HIV, 16 patients (19%) were on ARVs whilst 52 
patients (62%) were not on ARVs at time of admission and initiation of dialysis. This is 
consistent with a previous South African study that had 17.1% of patients on ARVs (81). 
The mean CD4 count of patients on ARVs was 240 (range 106-621) compared to the ARV 
naïve group with a median CD4 count of 83 (range 4-572).  
 
 
The causes of kidney injury in HIV positive and negative patients are outlined in Table 10 
and 11. HIV positive patients most frequently had kidney injury secondary to ATN due to 
sepsis. This occurred in 53 patients (63%) of HIV positive patients. Vachiat et al found that 
sepsis accounted for AKI in 62% of the HIV positive patients compared to 43% in the HIV 
negative group (40). 
 
 
 63 
HIV related kidney injury occurred in 44 of the 83 patients (53%). This was diagnosed on 
either biopsy or clinical suspicion which was confirmed with other auxillary investigations 
such as sonographical findings, urine PCR and blood investigations. These rates are similar 
to previous studies done at CHBAH in 2006 which showed incidence rates of 27% and 21% 
of HIVAN and HIVICK respectively (70).  
 
4.5 The pre-dialysis blood urea and serum creatinine and outcomes 
 
 
Initiation of dialysis is often based on clinical grounds and biochemical changes. Our study 
assessed the pre-dialysis blood urea and serum creatinine on the day that dialysis was 
initiated. These values were compared to outcomes. The pre-dialysis blood urea and serum 
creatinine levels are represented in Table 15 and 16 respectively.  
 
 
The pre-dialysis blood urea was significantly lower in the group that had renal recovery (p 
<0.0001). The mean blood urea level for patients with renal recovery was 34±19 mmol/l. 
This was much lower compared to the other groups; 49±20 mmol/l(transfer to chronic renal 
replacement), 51±22 mmol/l(transfer to ROPD), 45±23 mmol/l (death). A study in Belgium 
showed that there was no significant difference in the level of blood urea at dialysis and 
relationship to outcomes (132). This retrospective review, however, was done exclusively in 
an ICU setting and hence has limitations regarding extrapolation to our study population. 
Another study by Liu et al showed that blood urea levels at time of initiation had a strong 
correlation with mortality measured at 60 days after initiation of dialysis (109). This finding is 
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strongly supported by our study as the lower the urea at initiation of dialysis, the better the 
outcome.  
 
 
 Serum creatinine levels form the baseline of the widely used RIFLE criteria (11).  In 
addition to pre-dialysis blood urea levels, our study evaluated the pre-dialysis serum 
creatinine levels and compared this to outcomes. All groups had a substantially lower  
serum creatinine level at initiation of dialysis for renal recovery compared to other groups 
that did not recover renal function. The Cape Town study that assessed HIV positive 
patients, showed that better outcomes were observed in patients that had pre-dialysis 
serum creatinine levels of <1230 μmol/l. This study showed that renal recovery occurred 
with a median pre-dialysis serum creatinine level of 902 μmol/l compared to a pre-dialysis 
serum creatinine of 1022 μmol/l for patients that required chronic renal replacement and 
levels of 937 μmol/l for those that demised (81). In our cohort, the average pre-dialysis 
serum creatinine for HIV positive patients with renal recovery was 805 μmol/l compared to 
serum creatinine of greater than 1000 μmol/l for both patient groups, that were either 
transferred to chronic renal replacement or demised. 
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4.6 Outcomes in all patients with kidney injury   
The outcomes measured in our study were defined as renal recovery, transfer to chronic  
RRT, transfer to ROPD, Death or loss to follow up. The mortality rate was 23%. Previous 
studies done in India had mortality rates of 26.7% and 29.2% respectively (117, 130). 
Overall mortality rates from a developed countries as seen in the Madrid study had similar 
mortality rates from AKI of 26.7% (29). 
 
 
Renal recovery was achieved in 98 patients (31%). Similar findings were observed in the  
Cape Town study with renal recovery independent of dialysis of 33.3% (81). In a large 
population based study conducted in Alberta, Canada, 61.8% of patients with AKI had renal 
recovery (116). Transfer to chronic renal replacement therapy occurred in 23% of our 
cohort. This is slighty more than the Indian study that showed that 15% of patients required 
chronic dialysis (117). The large numbers in our study is directly related to the greater 
proportion of patients that had already established chronic kidney disease with an acute 
component, likely accounting for the difference. 
 
 
The highest mortality was noted in the HIV related kidney disease and ATN groups with 
43% and 41.9% respectively. Sepsis was the major contributor to the ATN group. This is 
consistent with the Indian studies that had rates from 24%-46% (117, 120). The underlying 
cause of sepsis was not reviewed in our study.  
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Pregnancy induced kidney injury had the highest rate of renal recovery, with 92% of 
patients recovering their kidney function and 0% mortality rate. This group also had the 
lowest pre-dialysis serum urea and creatinine compared to all other groups, as expected 
due to the hyperfiltration seen in pregnancy as well as increased surveillance for dialysis in 
this group. 79% of patients with malaria and AKI had recovery of their kidney function. This 
rate was slightly lower than observed in a prospective study by Shukla et al that showed an 
86% renal recovery rate (133). The mortality rate for malaria with AKI ranges from 15-50% 
(87). Our mortality rate for malaria with AKI was 5%; this difference in mortality is largely 
related to the exclusion of patients that were solely admitted to ICU.  
 
4.7 Outcomes based on HIV status 
 
Thirty patients (36%) in the HIV positive group had renal recovery compared to 58 patients 
(26%) who were HIV negative. The HIV negative group however had a lower mortality with 
only 19% demising compared to 34% in the HIV positive group. These findings were 
statistically significant (p value <0.0001). This is  similar to findings elsewhere in the world, 
with rates ranging between 26%-43.3% (80, 134). In South Africa, Arendse et al found a 
33.3% recovery rate, however this study had a higher mortality rate of 41% (81). Vachiat et 
al showed a mortality rate of 44% but showed no statistical difference in outcome between 
HIV positive and negative patients that were dialysed.  
 
The CD4 counts were also reviewed and compared to outcomes. 46% of patients with CD4 
counts of greater than 200 cells/μl had renal recovery compared to 30% of patients with 
CD4 counts less than 200 cells/μl. Lower CD4 counts also contributed to a higher mortality 
of 38% compared to their counterparts with higher CD4 counts that had a mortality rate of 
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26%. Our study showed no statistical significance (p value 0.5857) between patients that 
had AKI and CD4 less than 200 cells/μl and CD4 greater than 200 cells/μl. The Cape Town 
based study showed a better outcome in patients with AKI and CD4 counts greater than 
200 cells/μl (81). 
 
Patients’ ARV status and  relationship to outcomes were also assessed. Patients that were 
not on ARVs at the time of initiation of dialysis had a 37% rate of renal recovery compared 
to 19% in patients that were on ARVs. The mortality rate of patients on ARVs was slightly 
higher than those patient not on ARVs (37.5% vs 33%); this finding however was not 
statistically significant (p = 0.5857) and is likely related to the low numbers in the two 
groups. Arendse et al reported a mortality rate of 22.9% for patients on ARVs (p =0.133) 
(81).  
 
4.8 Limitations 
 
This was a retrospective review of all patients that were dialysed acutely at CHBAH and 
hence several limitations are evident. The records were reviewed from a computer based 
system, known as BART. The input of variables is subject to the attending doctor in charge 
of the case. Variables such as the hepatitis serology and ARV status were not well captured 
and may well have an influence on some analyses.  
 
Another important confounder was the large group of ‘Decompensated chronic kidney 
disease’. This large proportion of patients included those that had a documented element of 
chronic kidney disease and were initiated on dialysis. The reasons for the acute 
deterioration of renal function in this group were not subanalysed.  
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The “transfer to ROPD” group included all patients whereby acute dialysis was stopped in 
patients that did not achieve renal recovery. The eGFR at the cessation of dialysis was not 
evaluated and hence patients that were in a stable state, albeit still chronic were not 
separately evaluated, leading to biasness. 
 
Definitive causes of kidney disease in the HIV positive group were not established on basis 
of biopsy. This is a major limitation, particularly when assessing the ‘HIV related kidney 
disease” group that comprised of HIVAN and HIVICK, which can only be diagnosed 
definitively by histology, but were assessed on the basis of other auxiliary investigations in 
making a presumptive diagnosis. HIV related chronic kidney disease would be a better 
reflection of this group. 
 
The numbers of patients that were subanalysed in certain groups such as HIV positive 
patients were not large. This, as seen in the ARV status and outcomes may not be a true 
reflection of the relationship. 
 
ICU makes up an integral part of any hospital and AKI in the critically ill patient makes up a 
large percentage of this disease profile in hospitals. The exclusion of patients admitted to 
ICU and managed for AKI was not reviewed in this study and hence would have skewed 
mortality and outcomes. 
 
Outcomes were defined in 5 groups which included renal recovery, transfer to chronic RRT, 
transfer to ROPD, death and unknown outcomes. Renal recovery however was assessed as 
normalization of renal function and independence of dialysis at a point in time. A repeat 
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serum creatinine for all outcomes was not assessed at a 3 month interval from initiation of 
dialysis and hence cannot truly reflect the definition of AKI according to the RIFLE criteria. 
 
4.8 Recommendations    
Acute kidney injury is a common presentation of disease within our setting. Further studies 
need to evaluate the actual number of patients with AKI in our hospitals irrespective of the 
initiation of dialysis and relate this to outcomes. Closer monitoring of blood urea and serum 
creatinine particularly after 3 months needs to be assessed, so that the fulfillment of the 
RIFLE criteria for AKI can be established.  A prospective study design assessing these 
parameters is recommended. 
 
4.9 Conclusion 
 
Acute kidney injury with subsequent initiation of dialysis is a major component in medical 
practice and has a high mortality rate. Economic and social factors play a massive role in 
initiation of dialysis in South African state health care facilities. Our audit shows that the 
leading causes of AKI with subsequent initiation of dialysis included decompensated chronic 
kidney disease, ATN, pregnancy induced kidney injury, malaria, HIV related kidney injury 
and GN. Acute tubular necrosis was the one of leading causes in both HIV positive and 
negative patients with a high mortality rate in both groups.  HIV positive patients had a 
higher renal recovery rate compared to their HIV negative counterparts, however mortality 
was overall higher in HIV positive patients; however those with higher CD4 counts had an 
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overall improved outcome. Earlier dialysis had a superior outcome in all patients, including 
HIV positive patients. 
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CHAPTER 6: APPENDIX  
APPENDIX A: Ethics clearance certificate  
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Appendix B: Data Collection Sheet 
Allocated Study number:__________   Patient Number:________ 
            
Age:_____       
        
Sex: Male Female     
        
Race: African Coloured White Indian   
      
            
HIV Status: Positive Negative Unknown    
        
If Positive: CD4 Count:_____      
        
If Positive: ARV Status: Yes No    
        
If ARV status Yes:Duration________      
            
      
            
Hepatitis B Positive Negative Unknown    
        
Hepatitis C Positive Negative Unknown    
            
      
            
Pre-dialysis Blood urea:________      
Pre-dialysis Serum creatinine:_________     
            
      
            
Underlying Primary Disease: 1.________ 2__________3_________4__________   
        
Underlying chronic comorbidities:      
  Hypertension  Yes No   
  Diabetes  Yes No   
  Malignancy  Yes No   
  Other:__________ Yes No   
        
Discipline of referral: Med Surg 
Obs & 
Gynea Other 
            
      
            
Outcomes: Renal Recovery  Yes No   
  Transfer to chronic RRT Yes No   
  Transfer to ROPD  Yes No   
  Death  Yes No   
  Loss to follow up  Yes No   
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Appendix C: Turnitin Letter from Supervisor                       
